How stress reduces sperm motility by altering mitochondria

An­oth­er phar­ma com­pa­ny is fac­ing sup­ply con­straints be­cause of third-par­ty con­tract man­u­fac­tur­ing is­sues. On Tues­day, Ther­at­e­ch­nolo­gies warned there is a risk its lipody­s­tro­phy drug for

Eywa’s facility boasts the potential for a capacity expansion of up to two billion tablets or capsules annually. Credit: mkfilm/Shutterstock.com. Biocon’s step-down, wholly owned subsidiary,